Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Reviewing Ravulizumab’s Long-Term Profile as New NMOSD Treatment
May 18th 2024Sean Pittock, MD, director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab’s approval.
FDA Grants Rare Pediatric Disease Designation to DMD Gene Therapy Candidate SGT-003
May 16th 2024Solid Biosciences is expecting to provide initial safety data on SGT-003 from the first couple of pediatric patients with Duchenne muscular dystrophy enrolled in the phase 1/2 INSPIRE Duchenne trial in mid-2024.
Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD
May 16th 2024The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]
The Promising Future of Gene Therapy in Treating Neurological Diseases: Michael Kaplitt, MD, PhD
May 15th 2024The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]
Eisai Commences Rolling BLA for Subcutaneous Autoinjector Form of Lecanemab
May 15th 2024The subcutaneous autoinjector, which facilitates 360 mg weekly maintenance dosing of lecanemab, takes less time to administer than the approved intravenous formulation and may lead to less hospital visits and nursing care.
Insights Into Nasal Pathways for Brain Protein Sampling and Treatment Delivery: Mony de Leon, EdD
May 15th 2024The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]
Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study
May 13th 2024Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.
CSF Anti-DAGLA Autoantibodies Identified as Potential Biomarker of Rapidly Progressive Cerebellitis
May 11th 2024A recent study recognized anti-DAGLA autoantibodies in the cerebrospinal fluid of a small group of patients, suggesting that it could be a potential biomarker for diagnosing cerebellar ataxia.